Sie sind hier: Startseite Reseachers Matthias Eder

Matthias Eder

Eder, Matthias
Prof. Dr. sc. hum.
Division of Radiopharmaceutical Development, Department of Nuclear Medicine, University
Medical Center, Hugstetter Straße 55, D-79106 Freiburg
matthias.eder[a]uniklinik-freiburg.de
 
Current position
Full Professor (W3) of Radiopharmaceutical Development, Department of Nuclear Medicine,
University Medical Center, Freiburg;
Head of Division of Radiopharmaceutical Development, DKTK Freiburg, German Cancer Research Center, Heidelberg

 

Research topic in GRK 2606: Substrate-like protease probes

 
University training and degree(s)
2001-2005       Study of Biotechnology, University of Applied Sciences, Mannheim
 
Advanced academic qualifications
2009                Dissertation in Radiopharmacy, German Cancer Research Center Heidelberg
 
Postgraduate Positions
Since 2017     Full Professor (W3) of Radiopharmaceutical Development, Department of
                       Nuclear Medicine, University Medical Center, Freiburg
Since 2017     Head of Division Radiopharmaceutical Development, DKTK Freiburg, German
                       Cancer Research Center, Heidelberg          
2015-2017      Research Group in the Clinical Cooperation Unit Nuclear Medicine,  
                       German Cancer Research Center and University Hospital, Heidelberg
2013-2015      Group Leader; “Radiopharmaceutical Sciences”, Division of 
                       Radiopharmaceutical Chemistry, German Cancer Research Center,
                       Heidelberg
2009-2013      Postdoc; Division Radiopharmaceutical Chemistry, German Cancer Research    
                       Center, Heidelberg
 
Other
2012               Dr. Emil Salzer Prize for Cancer Research
2014               EANM Springer Prize 2014 for the Best Clinical Paper
2015               International Best Abstracts Award, SNMMI annual meeting
2015               Berson-Yalow Award, Society of Nuclear Medicine
2015               Image of the Year Award, Society of Nuclear Medicine
2015               EANM Eckert & Ziegler Abstract Award 2015
2015               EANM Springer Prize · Best Paper 2015
2016               EANM Springer Prize · Best Paper 2016
2017               Image of the Year Award, Society of Nuclear Medicine
2017                EANM Springer Prize · Most cited paper 2017 - European Journal of Nuclear
2017               EANM Springer Prize · Best Paper 2017- European Journal of Nuclear Medicine and Molecular
2018               Erwin Schrödinger-Prize 2018, Helmholtz Association of German Research Centres
                       
10 important publications
  1. Eder, M., Knackmuss, S., Le Gall, F., Reusch, U., Rybin, V., Little, M., Haberkorn, U., Mier, W., and Eisenhut, M. (2010). (68)Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur. J. Nucl. Med. Mol. Imaging 37, 1397-407.
  2. Eder, M., Schafer, M., Bauder-Wust, U., Hull, W. E., Wangler, C., Mier, W., Haberkorn, U., and Eisenhut, M. (2012). (68)Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug. Chem. 23, 688-97.
  3. Eder, M., Lohr, T., Bauder-Wust, U., Reber, M., Mier, W., Schafer, M., Haberkorn, U., and Eisenhut, M. (2013). Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH)3-Conjugates in Important Organs. J. Nucl. Med. 54, 1-4.
  4. Eder, M., Eisenhut, M., Babich, J., and Haberkorn, U. (2013). PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 40, 819-23.
  5. Haberkorn, U., Eder, M., Kopka, K., Babich, J. W., and Eisenhut, M. (2016). New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 22, 9-15.
  6. Kratochwil, C., Giesel, F. L., Stefanova, M., Benesova, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., and Haberkorn, U. (2016). PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J. Nucl. Med. 57, 1170-6.
  7. Benesova, M., Schafer, M., Bauder-Wust, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., and Eder, M. (2015) Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J. Nucl. Med. 56, 914-20.
  8. Benesova, M., Bauder-Wust, U., Schafer, M., Klika, K. D., Mier, W., Haberkorn, U., Kopka, K., and Eder, M. (2016). Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J. Med. Chem. 59, 1761-75.
  9. Baranski, A. C., Schafer, M., Bauder-Wust, U., Wacker, A., Schmidt, J., Liolios, C., Mier, W., Haberkorn, U., Eisenhut, M., Kopka, K., and Eder, M. (2017). Improving the Imaging Contrast of (68)Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjug. Chem. 28, 2485-2492.
  10. Eder, M., S. Pavan, U. Bauder-Wust, K. van Rietschoten, A. C. Baranski, H. Harrison, S. Campbell, C. L. Stace, E. H. Walker, L. Chen, G. Bennett, G. Mudd, U. Schierbaum, K. Leotta, U. Haberkorn, K. Kopka and D. P. Teufel (2019). Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Res. 79, 841-852.